Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk

  • STATUS
    Recruiting
  • End date
    Sep 30, 2024
  • participants needed
    76
  • sponsor
    Massachusetts General Hospital
Updated on 18 February 2022
body mass index
cancer
hepatitis
growth hormone
vitamin e
MRI
hepatic failure
liver disease
hepatitis b surface antigen
fatty liver
steatosis
fats
vitamin
vitamins
magnetic resonance spectroscopy
steatohepatitis
proton magnetic resonance spectroscopy

Summary

Nonalcoholic fatty liver disease (NAFLD) is common in individuals with obesity and is a significant threat to public health, because it can lead to impaired liver function and liver failure. Growth hormone is a hormone produced in the pituitary gland that helps regulate metabolism and growth. Individuals with obesity, on average, secrete less growth hormone than individuals without obesity. There are data to suggest that growth hormone may help to reduce the amount of fat in the liver, and may also reduce inflammation in the liver, both of which would be helpful to individuals with NAFLD. The purpose of this study is to investigate whether treatment with a drug called tesamorelin, which is a growth hormone releasing hormone analogue, will decrease liver fat and improve liver inflammation and scarring in obese individuals with NAFLD.

Details
Condition Non-Alcoholic Fatty Liver Disease, Obesity, Obesity, Abdominal, Liver Fat, Fatty Liver
Treatment Tesamorelin, Identical Placebo
Clinical Study IdentifierNCT03375788
SponsorMassachusetts General Hospital
Last Modified on18 February 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Men and women 18-65yo
Body mass index (BMI) 30kg/m2, or, for participants with known steatohepatitis, BMI 25kg/m2
Hepatic steatosis as demonstrated by either a) Grade 1+ steatosis on a liver biopsy performed within 12 months of the baseline visit, without >10% reduction in body weight or addition of medications to treat fatty liver, or b) liver fat fraction 5% on hydrogen-magnetic resonance spectroscopy (1H-MRS)
Hepatitis C antibody and Hepatitis B surface antigen negative. Subjects without known history of Hepatitis C or Hepatitis C treatment who have a positive Hepatitis C antibody but a negative hepatitis C viral load will also be eligible
For females 50yo, negative mammogram within 1 year of baseline
If use of vitamin E 400 international units daily, stable dose for 6 mos
Up to date with colon cancer screening recommended by the participant's primary care physician, using whatever methodology the primary physician recommends. This will be ascertained by self-report. (If a participant does not have a primary care physician, we will discuss that colon cancer screening is recommended, typically starting at age 50y, and refer the participant to primary care through Partners if s/he desires.)

Exclusion Criteria

Heavy alcohol use defined as consumption of > 20 grams daily for women or > 30 grans daily for men for at least 3 consecutive months over the past 5 years assessed using the Lifetime Drinking History Questionnaire
Known diagnosis of diabetes, use of any anti-diabetic medications (including thiazolidinediones or metformin), fasting glucose >126mg/dL, or hemoglobin A1c (HbA1c) 6.5%. Participants with stable use of metformin 6 months will be permitted if it is being used for pre-diabetes or another non-diabetes indication (e.g., PCOS)
Use of any specific pharmacological treatments for NAFLD/nonalcoholic steatohepatitis except vitamin E
Known cirrhosis, Child-Pugh score 7, stage 4 fibrosis on biopsy, or clinical evidence of cirrhosis or portal hypertension on imaging or exam. If a subject is not known to be cirrhotic at screen but is found to be cirrhotic based on the results of liver biopsy at baseline, this subject will be referred to a hepatologist for clinical care and will be excluded from further participation in the study
Chronic systemic corticosteroid use in the 6 months prior to the baseline visit
Chronic use of Actigall, methotrexate, amiodarone, or tamoxifen
Known diagnosis of alpha-1 antitrypsin deficiency, Wilson's disease, hemochromatosis, or autoimmune hepatitis
Use of growth hormone or growth hormone releasing hormone within the past 6 months
Change in lipid lowering or anti-hypertensive regimen within 2 months of screening
Hemoglobin < 10.0 g/dL or Creatinine >1.5mg/dL
Active malignancy
For men, history of prostate cancer or evidence of prostate malignancy by prostate specific antigen (PSA) > 5 ng/mL
Severe chronic illness judged by the investigator to present a contraindication to participation
History of hypopituitarism, head irradiation or any other condition known to affect the GH axis
Use of physiologic testosterone (men) or estrogen or progesterone (women) unless stable use for a year or more prior to study entry
Routine magnetic resonance imaging (MRI) exclusion criteria such as the presence of a pacemaker or cerebral aneurysm clip
Weight loss surgery within 1 year before baseline. Weight loss surgery more than 1 year prior to baseline visit is permissible as long as no active weight loss (<10% decrease in weight over past 6 months)
For women, positive urine pregnancy test (hCG), trying to achieve pregnancy, or breastfeeding
For women able to become pregnant, unwillingness to use an acceptable form of birth control during the study
Known hypersensitivity to tesamorelin or mannitol
Contraindication to receiving beta-blocker or nitroglycerin (which are part of the coronary angiography)
Significant radiation exposure, including any history of radiation therapy, or any of the following in the 12 months prior to randomization: a) more than 2 percutaneous coronary interventions; b) more than 2 myocardial perfusion studies; 3) more than 2 computed tomography angiograms
Active consideration for a procedure or treatment that involves significant radiation exposure as defined above in the 12 months following randomization
Not willing or able to adhere to dose schedules and required procedures per protocol
Judged by the investigator to be inappropriate for the study for other reasons not detailed above
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note